BIASCA, Switzerland, March 24, 2016 /PRNewswire/ --
Helsinn wins in five categories; Quality, Reliability, Capabilities, Expertise and Compatibility, earning a place among the best in the industry, and also wins Individual Attribute Awards in the categories: Accessible Senior Management; State-of-the-Art; Innovation; Right the First Time; Strength of Science; On Time Delivery; Cultural Fit; and Reputation
Helsinn, the pharmaceutical Group focused on building quality cancer care, today announces that its Swiss manufacturing company, Helsinn Advanced Synthesis SA, has for the second year running received awards at the CMO Leadership Awards, which recognize the highest quality contract manufacturing organizations as chosen by real customers. "Industry Standard Research is honored to conduct the research for Life Science Leader's CMO Awards. ISR's stringent screening processes and the high caliber of qualification required to participate in our contract manufacturing benchmarking research means that real customers provide experiential feedback on their involvement with contract suppliers over the past 18 months. This enables users of ISR's research to make confident business decisions based on the experiences of their industry peers," Andrew Schafer, President of Industry Standard Research, commented.
This year Helsinn won in five categories; Quality, Reliability, Capabilities, Expertise and Compatibility, earning a place among the best in the industry. Helsinn's quality, expertise and commitment to its clients were recognized and highlighted at the presentation of the CMO Leadership Awards on 16 March 2016 at the W Hotel, Lexington Avenue, New York. In addition, for the first time, the CMO Awards also handed out Individual Attribute Awards in which Helsinn won in the following categories: Accessible Senior Management; State-of-the-Art; Innovation; Right the First Time; Strength of Science; On Time Delivery; Cultural Fit; and Reputation.
Life Science Leader (http://www.lifescienceleader.com/) developed the Awards in response to the historical challenge for clients in evaluating high quality CMO partners. The Awards recognize those CMOs that are most highly recognized by industry peers.
Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: "The Helsinn Group is celebrating its 40th anniversary in 2016 and believes its core values of respect, integrity and quality have been the backbone of four decades of success in helping patients enjoy a better quality of life. These core values are echoed in the CMO Leadership categories and Helsinn is honored to be a recipient of the award."
Waldo Mossi, Helsinn Advanced Synthesis' General Manager, said: "We are delighted to have won in five categories in this prestigious awards ceremony, in which we are recognized by our industry peers, who are our toughest judges. The award is a strong validation of the values which have helped Helsinn deliver the highest manufacturing quality for 40 years."
About the Helsinn Group
Helsinn is a privately owned cancer supportive care pharmaceutical group with an extensive portfolio of marketed products and a broad development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality, through a unique integrated licensing business model working with long standing partners in pharmaceuticals, medical devices and nutritional supplement products. Helsinn is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland and the US, a representative office in China, as well as a product presence in about 90 countries globally.
In 2016, our 40th anniversary year, you can meet representatives from Helsinn at:
- NCCN Annual Conference (Hollywood, FL, USA, 31 March-2 April)
- ASCO Annual Meeting (Chicago, USA, 3-7 June)
- MAASC Annual Meeting (Adelaide, Australia, 23-25 June)
- ChemOutsourcing Conference (Parsippany, New Jersey, 19-21 September)
- CPhI Worldwide (Barcelona, Spain, 4-6 October)
- ESMO Congress (Copenhagen, Denmark, 7-11 October)
- BioEurope (Köln, Germany, 4-6 November)
For more information, please visit http://www.helsinn.com.
About Helsinn Advanced Synthesis SA:
Helsinn Advanced Synthesis SA is the manufacturing division of the Helsinn Group and develops and manufactures APIs, cGMP Advanced Intermediates, a High Potency Active Ingredients (HPAIs) and Cytotoxic APIs for third parties from clinical phase to commercial supply on an exclusive basis. The production plant is located in Biasca, Switzerland. The Biasca site is routinely inspected by the FDA and other global regulatory agencies. Production scale ranges from grams (CYTO-HPAIs), up to tens of tons APIs in plants fully dedicated to cGMP manufacturing.
For more information, please contact:
Head of Communication & Press Office
Business Development Contact:
Helsinn Advanced Synthesis SA:
Director, Business Development